 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus RSV F Protein Vaccine VXA-RSV-f Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers 